In the treatment of MM patients, the MAbs targeting PD-1/PD-L1, including pembrolizumab, durvalumab and nivolumab, had been reported [10]; unfortunately, anti-PD-1/PD-L1 antibodies had poor therapeutic effect as a single agent [11]. This evidence concerns the gene PDCD1 and Miyoshi myopathy.